Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Mohammad Sadegh Fallahi; Nasibeh Zerangian; Atousa Ghorbani; Gisou Erabi; Melika Shirali; Elaheh Shabani; Foad Rommasi; Mahsa Mohammadi Najafabadi; Shima Karbasi; Samaneh Toutounchian; Ramin Ahangar-Sirous; Ava Motaghy; Mahsa Heidari; Niloofar Deravi

doi:10.2174/1573394719666230201122212

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi (Corresponding Author)

Research output: Contribution to journal › Review article › peer-review

Abstract

Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on understanding its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system leading to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underlying mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding.

Original language	English
Pages (from-to)	53-99
Number of pages	47
Journal	Current Cancer Therapy Reviews
Volume	20
Issue number	1
DOIs	https://doi.org/10.2174/1573394719666230201122212
Publication status	Published - 2024
Externally published	Yes

Keywords*

anti-cancer
chemotherapy
immunotherapy
lymphatic system
monoclonal antibodies
Non-Hodgkin lymphoma

Field of Science*

3.4 Medical biotechnology
3.1 Basic medicine
3.2 Clinical medicine
1.6 Biological sciences

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/1573394719666230201122212

Cite this

Fallahi, M. S., Zerangian, N., Ghorbani, A., Erabi, G., Shirali, M., Shabani, E., Rommasi, F., Najafabadi, M. M., Karbasi, S., Toutounchian, S., Ahangar-Sirous, R., Motaghy, A., Heidari, M., & Deravi, N. (2024). Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review. Current Cancer Therapy Reviews, 20(1), 53-99. https://doi.org/10.2174/1573394719666230201122212

@article{b4a5c5085a3f4e899059ab7d28d093b4,

title = "Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review",

abstract = "Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on understanding its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system leading to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underlying mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding.",

keywords = "anti-cancer, chemotherapy, immunotherapy, lymphatic system, monoclonal antibodies, Non-Hodgkin lymphoma",

author = "Fallahi, {Mohammad Sadegh} and Nasibeh Zerangian and Atousa Ghorbani and Gisou Erabi and Melika Shirali and Elaheh Shabani and Foad Rommasi and Najafabadi, {Mahsa Mohammadi} and Shima Karbasi and Samaneh Toutounchian and Ramin Ahangar-Sirous and Ava Motaghy and Mahsa Heidari and Niloofar Deravi",

note = "Publisher Copyright: {\textcopyright} 2024 Bentham Science Publishers.",

year = "2024",

doi = "10.2174/1573394719666230201122212",

language = "English",

volume = "20",

pages = "53--99",

journal = "Current Cancer Therapy Reviews",

issn = "1573-3947",

publisher = "Bentham Science Publishers",

number = "1",

}

Fallahi, MS, Zerangian, N, Ghorbani, A, Erabi, G, Shirali, M, Shabani, E, Rommasi, F, Najafabadi, MM, Karbasi, S, Toutounchian, S, Ahangar-Sirous, R, Motaghy, A, Heidari, M & Deravi, N 2024, 'Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review', Current Cancer Therapy Reviews, vol. 20, no. 1, pp. 53-99. https://doi.org/10.2174/1573394719666230201122212

TY - JOUR

T1 - Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma

T2 - A Literature Review

AU - Fallahi, Mohammad Sadegh

AU - Zerangian, Nasibeh

AU - Ghorbani, Atousa

AU - Erabi, Gisou

AU - Shirali, Melika

AU - Shabani, Elaheh

AU - Rommasi, Foad

AU - Najafabadi, Mahsa Mohammadi

AU - Karbasi, Shima

AU - Toutounchian, Samaneh

AU - Ahangar-Sirous, Ramin

AU - Motaghy, Ava

AU - Heidari, Mahsa

AU - Deravi, Niloofar

PY - 2024

Y1 - 2024

N2 - Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on understanding its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system leading to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underlying mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding.

AB - Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on understanding its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system leading to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underlying mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding.

KW - anti-cancer

KW - chemotherapy

KW - immunotherapy

KW - lymphatic system

KW - monoclonal antibodies

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85180689643&partnerID=8YFLogxK

U2 - 10.2174/1573394719666230201122212

DO - 10.2174/1573394719666230201122212

M3 - Review article

AN - SCOPUS:85180689643

SN - 1573-3947

VL - 20

SP - 53

EP - 99

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

IS - 1

ER -

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this